In our subgroup analysis, we found RAP1A expression in primary CRC tissues could stratify the clinical outcome of both stage II and III patients, suggesting RAP1A as a promising prognostic indicator for identifying risk population within the same TNM stage. The gene discussed is RAP1A; the disease is colorectal carcinoma.